Acute Intravenous Injection of Serelaxin (Recombinant Human Relaxin‐2) Causes Rapid and Sustained Bradykinin‐Mediated Vasorelaxation

BACKGROUND: A recent clinical trial (RELAXin in Acute Heart Failure [RELAX‐AHF]) demonstrated that 48 hours of continuous intravenous infusion of the vasorelaxant peptide serelaxin (recombinant human relaxin‐2) to patients with acute heart failure reduced cardiovascular mortality at 180 days. The pe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Leo, Chen Huei, Jelinic, Maria, Parkington, Helena C., Tare, Marianne, Parry, Laura J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Blackwell Publishing Ltd 2014
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3959707/
https://ncbi.nlm.nih.gov/pubmed/24584737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.113.000493
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge